A Phase III, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study to Evaluate the Efficacy and Safety of Once-Weekly RO7795068 Administered to Participants With Obesity or Overweight Without Type 2 Diabetes
Latest Information Update: 27 Jan 2026
At a glance
- Drugs CT-388 (Primary)
- Indications Obesity
- Focus Registrational; Therapeutic Use
- Acronyms Enith1
- Sponsors Roche
Most Recent Events
- 27 Jan 2026 New trial record